Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
SK Biopharmaceuticals announced that Health Canada has accepted Paladin Labs Inc.'s filing of a New Drug Submission (NDS) for cenobamate as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
read more
AstraZeneca’s new tablet formulation of CALQUENCE® (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL), which is approved under accelerated approval based on ...
read more
The mid-size pharmaceutical market is expected to grow from$6,51,349.9 million in 2021 to $10,00,584.3 million by 2028.
read more
Rani Therapeutics Holdings, a company focused on the oral delivery of biologics, announced that it has entered into a loan agreement with Avenue Venture Opportunities Fund for up to $45M of funding.
read more
The Indian Generic Drugs Market stood at $24.53B in 2022 and is expected to grow at a steady CAGR of 6.97% during the forecast period.
read more
Ascletis Pharma announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ASC10, an oral drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19, to conduct the Phase Ib clinical trial in mild-to-moderate COVID-19 patients.
read more
The global softgel capsules market is expected to reach$ 14.3B by 2030 owing to the rising prevalence of chronic diseases and increased R&D investments by the key players, according to Growth Plus Reports.
read more
The global market for cystic fibrosis therapeutics is projected to grow at a compound annual growth rate (CAGR) of 10% during the forecast period of 2022 to 2030, according to a report from Research & Markets.
read more
Tavanta Therapeutics, a pharmaceutical company announced the completion of patient enrollment in the company's l Phase 3 study for TAVT-45 (abiraterone acetate) Granules for Oral Suspension ("TAVT-45"). TAVT45CO2 is a global Phase 3 clinical trial evaluating TAVT-45 in patients with metastatic castrate-sensitive prostate cancer (mCSPC) and ...
read more
The global pharmaceutical excipients market is estimated to register growth at a CAGR of 5% during the forecast period 2019 - 2027, according to an assessment by Transparency Market Research (TMR).
read more
The global compounding pharmacy market size is estimated to be USD 9.2 billion and is expected to witness a CAGR of 9.45% to 2029.
read more
Bausch Health Companies and its gastroenterology business Salix Pharmaceuticals announced the U.S. District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. regarding the infringement and validity of certain U.S. Patents protecting the composition and use of XIFAXAN® (...
read more
In 2021, the global CBD market was valued at $4.20B. The market is projected to reach US$12.64 billion by 2026, according to a report by Research & Markets. Growing regulatory approvals is a major driver of the market. The CBD market is expected to grow at a CAGR of 25.53% during the forecast period of 2022-2026.
read more
Gilead Sciences announced results reinforcing Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a highly efficacious treatment option for a broad range of people with HIV, including individuals with HIV/hepatitis B (HBV) coinfection.
read more
The global pharmacy automation market reached a value of$ 5.4B in 2021, according to a report by Research & Markets. The report projects that the market will reach $8.6B by 2027, exhibiting a CAGR of 8.06% during 2021-2027.
read more